Clinical and haemodynamic outcomes in 658 patients receiving the Perceval sutureless aortic valve: early results from a prospective European multicentre study (the Cavalier Trial)

Abstract

The current 30-day results show that the Perceval valve is safe (favourable haemodynamic effect and low complication rate), and can be implanted with a fast and reproducible technique after a short learning period. Short cross-clamp and CPB times were achieved in both isolated and combined procedures. The Perceval valve represents a promising alternative to biological AVR, especially with a less invasive approach and in older patients.

Hemodynamic assessment of Perceval sutureless bioprosthesis by dobutamine stress echocardiography

“…When valve performance at rest is concerned, we observed similar results compared with other recently studies, either in terms of peak and mean gradients or in terms of EOA also when compared to a propensity‐matched cohort of patients undergoing TAVI . On the other hand, we observed slightly higher gradients in our multicenter European cohort of patients undergone AVR with Perceval sutureless bioprosthesis compared with a multicenter TAVI Italian experience (ITER registry) .…”

Direct Comparison of the Edwards Intuity Elite and Sorin Perceval S Rapid Deployment Aortic Valves

“…Doppler flow velocities were recorded from apical four-chamber view using pulsed and continuous wave Doppler mode to assess Abbreviations and Acronyms AV = atrioventricular AVR = aortic valve replacement CABG = coronary artery bypass graft surgery CPB = cardiopulmonary bypass EOA = effective orifice area EuroSCORE = European System for Cardiac Operative Risk Evaluation iEOA = indexed effective orifice area PVL = paravalvular leak RDAVR = rapid deployment aortic valve replacement RDV = rapid deployment valve peak and mean gradients. The indexed effective orifice area (iEOA; cm 2 /m 2 ) was determined using the effective orifice area (EOA) [4,5] divided by the patient body surface area. Severe patient-prosthesis mismatch was defined as an iEOA of less than 0.65 cm 2 /m 2 [15].…”

“…Rapid deployment valves (RDV) for AVR (RDAVR) have been introduced throughout the past years to facilitate shorter operation times and minimize surgical access while maintaining the advantages of surgical excision of degenerated aortic valve tissue [4][5][6][7]. Their design with expandable stents enables easy and rapid implant and thereby reduces cardiopulmonary bypass (CPB) and aortic clamp times while providing excellent hemodynamic performance when compared with conventional stented valve prostheses [4][5][6][8][9][10][11]. Importantly, early and midterm data show good durability and hemodynamic performance and low valve-related complications [6-8, 10, 12], and suggest that the use of RDAVR could be of clinical benefit for patients at high operative risk requiring combined procedures or minimally invasive AVR.…”

“…The self-expandable, stentless and sutureless Perceval S (Sorin Group Italia Srl, Saluggia, Italy) and the balloonexpandable, stented Intuity valve (Edwards Lifesciences, Irvine, CA) are the most frequently implanted RDV worldwide for AVR and were introduced in our program during the past 4 years [4][5][6]8]. Although accumulating evidence underscoring the safety and efficacy for both RDV has been recently published from prospective, single-armed multicenter trials or trials comparing RDAVR to conventional AVR [4][5][6]8], there are no data comparing both RDV directly. The aim of this singlecenter analysis was to directly compare both RDV with respect to early clinical outcomes, valve performance, and valve-related complications in patients undergoing AVR.…”

Clinical and hemodynamic outcomes of Perceval S sutureless bioprostheses implanted through a mini-approach in the aortic position

“…Ряд авторов в резюме трех последовательных пятилетних европейских мно-гоцентровых исследований (Pilot, Pivotal, Сavalier) по-жилой когорты пациентов (средний возраст 78,5 года) сообщили о благоприятных клинических и гемодина-мических результатах, включая низкие ранние и отсро-ченные показатели смертности (1,9 и 1,4 %), низкую частоту ранних параклапанных фистул (1,4%) [5,[11][12][13][14][15]. М. Eusanio [16] и К. Phan [4] описали бесшовное про-тезирование аортального клапана не только как много-обещающую альтернативу обычному протезированию, но также отметили хорошие функциональные гемоди-намические результаты с меньшим количеством ослож-нений.…”